bionomics.com.au (BNOX) - יתרות מזומנים למניה

Cash per share monitoring for Bionomics Limited (BNOX) demonstrates the impact of strict FDA control and high patent costs, with the metric holding around 0.47. Bionomics Limited (BNOX) is developing advanced therapies for PTSD and anxiety without the risk of dependence. Business stability is ensured by the neutral status of biomedicine, which minimizes the impact of global political upheavals on operational activities.
פילוחים אנליטיים של חברת Bionomics Limited

Bionomics Limited is optimizing costs by outsourcing the synthesis of neuro-drugs to third-party contractors in the US and Australia. Cash per share determines the portion of liquid capital attributable to a single security. This metric allows for the tracking of equity dilution during new issuances and the actual margin of safety. It is critical for investors to correlate this reserve with the cash burn rate. The cash per share trend over the period reveals the balance between financial stability and investment activity.